1. Home
  2. CHRD vs ABVX Comparison

CHRD vs ABVX Comparison

Compare CHRD & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chord Energy Corporation

CHRD

Chord Energy Corporation

HOLD

Current Price

$112.28

Market Cap

8.2B

Sector

Energy

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$134.00

Market Cap

7.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHRD
ABVX
Founded
2007
2013
Country
United States
France
Employees
676
69
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
7.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CHRD
ABVX
Price
$112.28
$134.00
Analyst Decision
Buy
Buy
Analyst Count
13
13
Target Price
$149.17
$131.31
AVG Volume (30 Days)
804.9K
2.6M
Earning Date
05-05-2026
03-23-2026
Dividend Yield
3.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.56
$52.14
Revenue Next Year
N/A
$4,132.27
P/E Ratio
$34.53
N/A
Revenue Growth
N/A
N/A
52 Week Low
$84.25
$7.70
52 Week High
$151.95
$148.83

Technical Indicators

Market Signals
Indicator
CHRD
ABVX
Relative Strength Index (RSI) 26.29 66.37
Support Level $86.73 $107.67
Resistance Level $150.29 $148.83
Average True Range (ATR) 3.99 7.44
MACD -1.49 4.14
Stochastic Oscillator 0.99 91.26

Price Performance

Historical Comparison
CHRD
ABVX

About CHRD Chord Energy Corporation

Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: